# Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens

> **NCT07689006** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 341 (actual)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** Pomalidomide-containing regimens
- **DRUG:** Non-pomalidomide-containing regimens

## Key facts

- **NCT ID:** NCT07689006
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-23
- **Primary completion:** 2025-03-28
- **Final completion:** 2025-03-28
- **Target enrollment:** 341 (ACTUAL)
- **Last updated:** 2026-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07689006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07689006, "Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07689006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*